Eosinophil-associated diseases (EADs) are a range of heterogeneous conditions in which eosinophils are believed to play a critical pathological role. EADs also include rare conditions such as hypereosinophilic syndromes (HES), eosinophilic granulomatosis with polyangitiis (EGPA), and eosinophilic gastrointestinal disorders (EGIDs). Several novel biological therapeutic strategies have been introduced in recent years that target eosinophils  directly or indirectly. These therapies can lead to improved treatment of EADs. We planned to establish an EAACI Task Force which will review and analyse currently available evidence about the usage of biologics in EADs in order to provide a position paper for clinical application.

WG Biologicals (Basic & Clinical Immunology Section)

Chair: Alessandra Vultaggio

Secretary: Andrea Matucci